Gut microbiota-driven metabolic reprogramming is a key contributor to Parkinson's disease with REM sleep behavior disorder
This study found that PD patients with RBD exhibit distinctive metabolic disturbances, including accumulation of gut microbiota-derived toxic aromatic amino acid catabolites, which were also observed in idiopathic RBD patients. The research integrated metabolomics, proteomics, and metagenomics to show that gut microbial dysbiosis drives a functional shift from fiber fermentation to enhanced protein and mucin degradation, associated with exacerbated oxidative stress and neuroinflammation.
This article is automatically generated from the structured evidence profile behind the claim above. Scores reflect the quality and quantity of available research, not clinical advice.
Gut microbiota-driven metabolic reprogramming is a key contributor to Parkinson's disease with REM sleep behavior disorder The current body of evidence comprises 1 study. EvidenceHub rates the overall confidence at 32/100 (low).
The Claim
Gut microbiota-driven metabolic reprogramming is a key contributor to Parkinson's disease with REM sleep behavior disorder
This conclusion is most relevant to: Parkinson's disease patients with and without RBD, and idiopathic RBD patients (prodromal stage of PD).
What the Research Shows
The conclusion draws on 1 linked study. Highlights from the cited literature:
- ▸Distinct metabolomic and proteomic signatures in Parkinson's disease patients with REM sleep behavior disorder. (Signal transduction and targeted therapy, 2026) —
How It Works
The proposed biological pathway:
- ▸Gut microbial dysbiosis in RBD-PD and iRBD reduces dietary fiber fermentation
- ▸Dysbiosis enhances degradation of protein, aromatic amino acids, glycine, and intestinal mucin glycans
- ▸This leads to accumulation of toxic aromatic amino acid catabolites
- ▸Result: Exacerbated oxidative stress, neuroinflammation, and accelerated pathological progression in PD
Who Might Benefit
Evidence fit by population:
- ▸Parkinson's disease patients with and without RBD, and idiopathic RBD patients (prodromal stage of PD)
Recommended Dose
N/A
Limitations & Caveats
Important context when interpreting this evidence:
- ▸Abstract does not specify sample size or provide statistical effect sizes for key findings
- ▸Causal inference is limited as the study is observational and cross-sectional in nature
- ▸The study does not report whether confounding factors (e.g., medication, diet) were controlled for
Frequently Asked Questions
What is REM sleep behavior disorder (RBD) and how common is it in Parkinson's disease?▼
RBD is a sleep disorder where people physically act out vivid dreams. It affects 40-50% of Parkinson's disease patients and is considered the most specific prodromal marker of PD.
What metabolic changes were found in PD patients with RBD?▼
PD patients with RBD showed a shift from TCA cycle to glycolysis, dysregulated urea cycle, lipid remodeling, and accumulation of gut microbiota-derived toxic aromatic amino acid catabolites.
How does gut microbiota contribute to Parkinson's disease with RBD?▼
Gut microbial dysbiosis drives a functional shift away from fiber fermentation toward enhanced degradation of protein, aromatic amino acids, and intestinal mucin glycans, leading to increased oxidative stress and neuroinflammation.
Were these metabolic changes also seen in people with idiopathic RBD?▼
Yes, the same metabolic disturbances, including accumulation of toxic aromatic amino acid catabolites, were observed in idiopathic RBD patients, who represent the prodromal stage of Parkinson's disease.
References
- 1.Shao Y, Wang J, Liu Y, Ni Y, Liu Z, Li Y, Jia Q, Li Q, Wang X, Li T, Liu M, Zhang S, Guo Y, Guo X, Wang D, Liu Y, Liu C, Cai H, Ning Y, Zhang J, Xu G, Le W. “Distinct metabolomic and proteomic signatures in Parkinson's disease patients with REM sleep behavior disorder..” Signal transduction and targeted therapy, 2026. PMID: 41912482 DOI: 10.1038/s41392-026-02613-8